Administration of recombinant human activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease

Neuroscience

Volumn 92, Issue 1, 1999, Pages 197-209

  Hughes, P E ^a   Alexi, T ^a   Williams, C E ^a   Clark, R G ^a   Gluckman, P D ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Calbindin; Cholinergic; GABA; Inhibin; Striatum; Transforming growth factor

Indexed keywords

4 AMINOBUTYRIC ACID; ACTIVIN A; CALBINDIN; CALRETININ; GLUTAMATE DEHYDROGENASE; QUINOLINIC ACID; RECOMBINANT PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; INTERNEURON; MALE; MOLECULAR CLONING; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ACTIVINS; ANIMALS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CHOLINE O-ACETYLTRANSFERASE; CORPUS STRIATUM; GAMMA-AMINOBUTYRIC ACID; HUMANS; HUNTINGTON DISEASE; INHIBINS; INTERNEURONS; MALE; NERVE GROWTH FACTORS; NEURONS; PHENOTYPE; QUINOLINIC ACID; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SYNAPTIC TRANSMISSION;

EID: 0033041786     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00724-6     Document Type: Article

References (76)

1. Alexi T., Venero J.L., Hefti F. Protective effects of neurotrophin-4/5 and transforming growth factor-α on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid. Neuroscience. 78:1997;73-86.
2. Anderson K.D., Panayotatos N., Corcoran T.L., Lindsay R.M., Wiegand S.J. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc. natn. Acad. Sci. U.S.A. 93:1996;7346-7351.
3. Andreasson K., Worley P.F. Induction of β-A activin expression by synaptic activity and during neocortical development. Neuroscience. 69:1995;781-796.
4. Baimbridge K.G., Celio M.R., Rogers J.H. Calcium-binding proteins in the nervous system. Trends Neurosci. 15:1992;303-308.
5. Beal M.F., Kowall N.W., Ellison D.W., Mazurekm M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
6. Bengtsson H., Soderstrom S., Ebendal T. Expression of activin receptors type I and II only partially overlaps in the nervous system. NeuroReport. 7:1995;113-116.
7. Bennett B.D., Bolam J.P. Characterization of calretinin-immunoreactive structures in the striatum of the rat. Brain Res. 609:1993;137-148.
8. 28K-immunoreactive neurons in the striatum of the rat. Brain Res. 610:1993;305-310.
9. Bilezikjian L.M., Vale W.W. Local extragonadal roles of Activins. Trends Endocrinol. Metab. 3:1992;218-223.
10. Bird E.D., Iversen L.L. Huntington's chorea: post mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in the basal ganglia. Brain. 97:1974;457-472.
11. Burger H. G., Findlay J. K. and Robertson D. M. (1996) Inhibin/Activin/Follistatin. In Reproductive Endocrinology, Surgery and Technology (eds Adashi E. Y., Rock J. A. and Rosenwaks Z.), pp. 801-826. Lippincott-Raven, Philadelphia.
12. Cameron V.A., Nishimura E., Mathews L.S., Lewis K.A., Sawchenko P.E., Vale W.W. Hybridization histochemical localization of activin receptor subtypes in rat brain, pituitary, ovary and testis. Endocrine Soc. 134:1994;799-808.
13. Celio M.R. CalbindinD-28K and parvalbumin in the rat nervous system. Neuroscience. 35:1990;375-475.
14. Chiu R., Angel P., Karin M. Jun-B differs in its biological properties and is a negative regulator of c-Jun. Cell. 59:1989;979-986.
15. Cowan R.L., Wilson C.J., Emson P.C., Heizmann C.W. Parvalbumin-containing GABAergic interneurons in the rat neostriatum. J. comp. Neurol. 302:1990;197-205.
16. Davies S.W., Beardsall K. Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurons. Neurosci. Lett. 140:1992;161-164.
17. DiFiglia M. Excitotoxic lesioning of the neostriatum: a model for Huntington's disease. Trends Neurosci. 13:1990;286-289.
18. DiFiglia M., Christakos S., Aronin N. Ultrastructural localization of immunoreactive calbindin-D28K in the rat and monkey basal ganglia, including subcellular distribution with colloidal gold labeling. J. comp. Neurol. 279:1989;653-665.
19. Dragunow M., Young D., Hughes P., MacGibbon G., Lawlor P., Singleton K., Sirimanne E., Beilharz E., Gluckman P. Is c-Jun involved in nerve cell death following status epilepticus and hypoxic-ischemic injury? Molec. Brain Res. 18:1993;347-352.
20. Emerich D.F., Lindner M.D., Winn S.R., Chen E.-Y., Frydel B.R., Kordower J.H. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. 16:1996;5168-5181.
21. Emerich D.F., Winn S.R., Hantraye P.M., Peschanski M., Chen E.-Y., Chu Y., McDermott P., Edward Baetge E., Kordower J.H. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature. 386:1997;395-399.
22. Fann M.-J., Patterson P.H. Neuropoietic cytokines and activin A differentially regulate the phenotype of cultured sympathetic neurons. Proc. natn. Acad. Sci. U.S.A. 91:1994;43-47.
23. Fann M.-J., Patterson P.H. Depolarization differentially regulates the effects of bone morphogenetic protein (BMP)-2, BMP-6 and activinA on sympathetic neuronal phenotype. J. Neurochem. 63:1994;2074-2079.
24. Ferrante R.J., Beal M.F., Kowall N.W., Richardson E.P. Jr., Martin J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 411:1987;162-166.
25. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P. Jr., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 230:1985;561-563.
26. Frim D.M., Uhler T.A., Priscilla Short M., Diala Ezzedine Z., Klagsbrun M., Breakefield X.O., Isacson O. Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. NeuroReport. 4:1993;367-370.
27. Funaba M., Murata T., Fujimura H., Murata E., Abe M., Torii K. Immunolocalization of type I or type II activin receptors in the rat brain. J. Neuroendocr. 9:1997;105-111.
28. Gaddy-Kurten D., Tsuchida K., Vale W. Activins and the receptor serine kinase superfamily. Recent Prog. Hormone Res. 50:1995;109-129.
29. Gerfen C.R., Baimbridge K.G., Miller J.J. The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. natn. Acad. Sci. U.S.A. 82:1985;8780-8784.
30. Haque N. S. K., Borghesani P. and Isacson O. (1997) Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder. Mol. Med. Today April, 175-183.
31. Hashimoto M., Gaddy-Kurten D., Vale W. Protooncogene junB as a target for activin actions. Endocrinology. 133:1993;1934-1940.
32. Hefti F (1997). Trophic factors as neuroprotective agents. In Neuroprotection in CNS Diseases (eds Bär P. R. and Beal M. F.), pp. 243-252. Marcel Dekker, New York.
33. Hughes P.E., Alexi T., Walton M., Williams C.E., Dragunow M., Clark R.G., Gluckman P.D. Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the CNS. Prog. Neurobiol. 57:1999;421-450.
34. Hughes P., Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmac. Rev. 47:1995;133-178.
35. Inokuchi K., Kato A., Hiraia K., Hishinuma F., Inoue M., Ozawa F. Increase in activin βA mRNA in rat hippocampus during long-term potentiation. Fedn Eur. biochem. Socs Lett. 382:1996;48-52.
36. Jacobowitz D.M., Winsky L. Immunocytochemical localization of calretinin in the forebrain of the rat. J. comp. Neurol. 304:1991;198-218.
37. Jakeman L., Mather J., Woodruff T. In vitro ligand binding of 125I-recombinant human activin A to the female rat brain. Endocrine Soc. 131:1992;3117-3119.
38. Kaufman D.L., Houser C.R., Tobin A.J. Two forms of the γ-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J. Neurochem. 56:1991;720-723.
39. Kawaguchi Y., Wilson C.J., Augood S.J., Emson P.C. Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci. 18:1995;527-535.
40. Kita H., Kosaka T., Heizmann C.W. Parvalbumin-immunoreactive neurons in the rat neostriatum: a light and electron microscope study. Brain Res. 536:1990;1-15.
41. 28K as a marker for the degeneration of the striatonigral pathway in Huntington's disease. Brain Res. 525:1990;209-214.
42. Krieglstein K., Suter-Crazzolara C., Fischer W.H., Unsicker K. TGF-β superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. Eur. molec. Biol. Org. J. 14:1995;736-742.
43. Kubota Y., Mikawa S., Kawaguchi Y. Neostriatal GABAergic interneurons contain NOS, calretinin or parvalbumin. NeuroReport. 5:1993;205-208.
44. Lai M., Gluckman P., Dragunow M., Hughes P.E. Focal brain injury increases activinβA mRNA expression in hippocampal neurons. NeuroReport. 8:1997;2691-2694.
45. Lai M., Sirimanne E., Williams C.E., Gluckman P.D. Sequential patterns of inhibin subunit gene expression following hypoxic-ischemic injury in the rat brain. Neuroscience. 70:1996;1013-1024.
46. Legerski R., Zhou X., Dresback J., Eberspaecher H., McKinney S., Segarini P., de Crombrugghe B. Molecular cloning and characterization of a novel rat activin receptor. Biochem. biophys. Res. Commun. 183:1992;672-679.
47. Lewen A., Soderstrom S., Hillered L., Ebendal T. Expression of serine/threonine kinase receptors in traumatic brain injury. NeuroReport. 8:1997;475-479.
48. Lin L.F.H., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
49. Ling N., Ying S., Ueno N., Esch F., Denoroy L., Guillemin R. Isolation and partial characterization of a Mr 32,000 protein with inhibin activity from porcine follicular fluid. Proc. natn. Acad. Sci. U.S.A. 82:1985;7217-7221.
50. Martinez-Serrano A., Bjorklund A. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J. Neurosci. 16:1996;4604-4616.
51. Mathews L.S., Vale W.W. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell. 65:1991;973-982.
52. McCullagh G.R. Dual endocrine activity of the testes. Science. 76:1932;19-20.
53. Mehler M.F., Mabie P.C., Zhang D., Kessler J.A. Bone morphogenetic proteins in the nervous system. Trends Neurosci. 20:1997;309-317.
54. Morita N., Takumi T., Kiyama H. Distinct localization of two serine-threonine kinase receptors for activin and TGF-β in the rat brain and down-regulation of type I activin receptor during peripheral nerve regeneration. Molec. Brain Res. 42:1996;263-271.
55. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic, Sydney.
56. Perez-Navarro E., Alberch J., Arenas E., Calvo N., Marsal J. Nerve growth factor and basic fibroblast growth factor protect cholinergic neurons against quinolinic acid excitotoxicity in rat neostriatum. Eur. J. Neurosci. 6:1994;706-711.
57. Portera-Cailliau C., Hedreen J.C., Price D.L., Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15:1995;3775-3787.
58. Prehn J.H.M., Bindokas V.P., Marcuccilli C.J., Krajewski S., Reed J.C., Miller R.J. Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type β confers wide-ranging protection on rat hippocampal neurons. Proc. natn. Acad. Sci. U.S.A. 91:1994;12599-12603.
59. Purkiss R.J., Legg M.D., Hunt S.P., Davies S.W. Immediate-early gene expression in the rat forebrain following striatal infusion of quinolinic acid. Eur. J. Neurosci. 5:1993;1653-1662.
60. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington's disease. Proc. natn. Acad. Sci. U.S.A. 85:1988;5733-5737.
61. Rivier J., Speiss J., McClintock R., Vaughan J., Vale W. Purification and partial characterization of inhibin from porcine follicular fluid. Biochem. biophys. Res. Commun. 133:1985;120-127.
62. Roberts R.C., DiFiglia M. Short- and long-term survival of large neurons in the excitotoxic lesioned rat caudate nucleus: a light and electron microscopic study. Synapse. 3:1989;363-371.
63. Roberts V.J., Barth S.L., Meunier H., Vale W. Hybridization histochemical and immunohistochemical localization of inhibin/activin subunits and messenger ribonucleic acids in the rat brain. J. comp. Neurol. 364:1996;473-493.
64. Roberts V.J., Sawchenko P.E., Vale W. Expression of inhibin/activin subunit messenger ribonucleic acids during rat embryogenesis. Endocrinology. 128:1991;3122-3129.
65. Sawchenko P.E., Plotsky P.M., Pfeiffer S.W., Cunningham E.T. Jr., Vaughan J., Rivier J., Vale W. Inhibin β in central neural pathways involved in the control of oxytocin secretion. Nature. 334:1988;615-617.
66. Schubert D., Kimura H., LaCorbiere M., Vaughan J., Karr D., Fischer W.H. Activin is a nerve cell survival molecule. Nature. 344:1990;868-870.
67. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 219:1983;316-318.
68. Shinozaki H., Ito I., Hasegawa Y., Nakamura K., Igarashi S., Nakamura M., Miyamoto K., Eto Y., Ibuki Y., Minegishi T. Cloning and sequencing of a rat type II activin receptor. Fedn Eur. biochem. Socs Lett. 312:1992;53-56.
69. Shutte J., Viallet J., Nau M., Segal S., Fedorko J., Minna J. Jun-B inhibits and c-fos stimulates the transforming and transactivatingf activities of c-Jun. Cell. 59:1989;987-997.
70. Takumi T., Moustakas A., Lin H.Y., Lodish H.F. Molecular characterization of a type I serine-threonine kinase receptor for TGF-β and activin in the rat pituitary tumor cell line GH3. Expl Cell Res. 216:1995;208-214.
71. ten Dijke P., Yamashita H., Ichijo H., Franzen P., Laiho M., Miyazono K., Heldin C-H. Characterization of type I receptors for transforming growth factor-β and Activin. Science. 264:1994;101-104.
72. The Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
73. Tretter Y.P., Munz B., Hubner G., Bruggencate G.T., Werner S., Alzheimer C. Strong induction of activin expression after hippocampal lesion. NeuroReport. 7:1996;1819-1823.
74. Tsuchida K., Mathews L.S., Vale W.V. Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor. Proc. natn. Acad. Sci. U.S.A. 90:1993;11,242-11,246.
75. Venero J.L., Beck K.D., Hefti F. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA. Neuroscience. 61:1994;257-268.
76. Venero J.L., Hefti F., Knusel B. Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: comparison between intraparenchymal and intraventricular administration. Molec. Pharmac. 49:1996;303-310.